{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2023"],"data_sharing_plan":["IPD Sharing (as of July 2023): No"],"condition":["Colorectal Neoplasms","Colorectal Cancer Metastatic"],"disease":["Colorectal Neoplasms","Colorectal Cancer Metastatic"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2751724"],"location":["China"],"study_start_month":["6"],"keyword":["Antineoplastic Agents, Immunological","Immunoglobulins","Antibodies","Antibodies, Monoclonal"],"repository":["ECRIN MDR"],"study_status":["Suspended"],"additional_accession":[]},"is_claimable":false,"name":"Evaluate the Efficacy, Safety and Tolerability of HLX26 and Serplulimab in Patients With mCRC","description":"This study is a phase II study to evaluate the efficacy, safety and tolerability of HLX26 and HLX10 in the treatment of patients with metastatic colorectal carcinoma that had received 3 prior therapies.","dates":{"creation":"2023-06-15"},"accession":"2751724","cross_references":{"ClinicalTrials___gov":["NCT05584137"]}}